IDAP, the IFPMA’s vision of innovation development and access pathways

The International Federation of Pharmaceutical Manufacturers and Associations proposed the IDAP (Innovation Development and Access Pathway) framework to streamline and, as far as possible, harmonise pathways for ensuring rapid authorisation and access to innovative medicines and vaccines, taking into account the specific characteristics of different countries.

2026 trends in pharmaceutical development

The introduction of artificial intelligence is one of the main drivers that will support the pharmaceutical industry’s final steps towards more innovative models, while facing legislative and regulatory innovation and geopolitical tensions. Biotech products are leading the way in innovative treatments

Many advancements in the setting up of the new pharmaceutical legislation

On 11 December 2025, the Trilogue reached an agreement on the final text of the “pharma package”, which includes the regulations and directives governing the development, production and commercialisation of medicinal products in the EU. The package now awaits formal adoption by the European Council and Parliament before it can enter into force. We summarise the main features of the reform of the European pharmaceutical legislation

Bacteriophages and AMR, the beginning of a new era?

The newly published EMA draft guideline on the quality aspects of phage therapy medicinal products paves the way for the use in Western Europe of this new - albeit century-old - approach to treating antibiotic-resistant infections

The UK’s new decentralised manufacturing framework

The new Decentralised Manufacturing Framework came into force on 23 July 2025. It enables the production of innovative medicines products such as cellular therapies close to the patients who will receive them. The framework covers both Point of Care manufacturing and Modular Manufacturing, and it requires prior authorisation and provides an alternative to traditional, centralised productions